There has been a sea change in how retina specialists treat retinal diseases, with a progressive shift toward more utilization of anti–vascular endothelial growth factor (VEGF), said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
There has been a sea change in how retina specialists treat retinal diseases, with a progressive shift toward more utilization of anti–vascular endothelial growth factor (VEGF), said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
Over the years of running the ASRS Preferences and Trends survey, have you seen any large shifts in responses to trends that are worth highlighting?
With the PAT survey, year over a year, we repeat some key questions to try to highlight important trends. Trends that we're often most interested in learning about are new technologies, new therapies that might be rapidly changing. For example, a couple of years ago, the FDA approval of the first ILM [internal limiting membrane]–staining agent—it’s a staining agent to help us perform macular surgery more effectively—this first agent was FDA approved, and prior to that, we were using an off-label agent. Over the past couple of years in the US, we saw rapid uptake in the utilization of this agent. This agent was actually approved earlier internationally, and over those prior years, we saw similar rapid increase in its uptake.
There have been some slower trends that we've been following closely as well. In the treatment of retinal diseases, there have really been sea changes in the way we perform things. For example, over the past 15 years, there has been a progressive shift toward utilization of more anti-VEGF therapy for treatment of retinal diseases, and we capture that with the PAT survey. Currently, there's a move toward, potentially, use of anti-VEGF therapy for treatment of retinal diseases that we previously did not treat, such as for severe nonproliferative diabetic retinopathy, something that we previously monitored. The PAT survey is in the process of capturing whether there really is a sea change or whether people will stick with their current habits.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More